IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities across multiple classes of precision medicine: direct targeting of oncogenic pathways – and synthetic lethality – which represents an emerging class of precision medicine targets. This diversified approach enables our objective to deliver the right medicine to the right patient to drive a more robust clinical response.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
September 24, 2020
August 31, 2020
August 12, 2020
September 17, 2020 at 4:40 PM EDT
September 14, 2020 at 11:30 AM EDT
September 10, 2020 at 3:45 PM EDT